Home > Insider Trading > Filing (0001209191-15-051413)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1459266	Zs Pharma Inc.	ZSPH	Pharmaceutical Preparations (2834)	263305698

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1198321	Farah Champsi	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1198325	Daniel Janney	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1198330	P Guy Nohra	One Embarcadero Center, Suite 3700 San Francisco CA 94111	Yes	No	Yes	No
1399763	Alta Partners Viii, L.p.	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No
1399894	Alta Partners Management Viii, Llc	One Embarcadero Center, Suite 3700 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-06-05	164,227	$57.88	2,657,843	No	4	S	Direct
Common Stock	Disposition	2015-06-08	11,200	$57.53	2,646,643	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $57.50 - $58.50, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
These shares were sold by Alta Partners VIII, L.P. ("APVIII"), the holder of record of the securities. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. Guy Nohra, Daniel Janney and Farah Champsi are managing directors of APMVIII and exercise shared voting and investment power with respect to the shares owned by APVIII. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein. Mr. Nohra is also a director of the issuer.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $57.50 - $57.65, inclusive. The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.